Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients

Abstract Aims/Introduction The relationship between pancreatic fatty infiltration and diabetes is widely known, whereas the causal relationship is not clear. Furthermore, it is uncertain whether pathogenesis of pancreatic fat is similar to that of liver fat. We aimed to clarify the contribution of t...

Full description

Bibliographic Details
Main Authors: Chisaki Ishibashi, Junji Kozawa, Yoshiya Hosakawa, Sho Yoneda, Takekazu Kimura, Yukari Fujita, Kenji Fukui, Hiromi Iwahashi, Iichiro Shimomura
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Journal of Diabetes Investigation
Subjects:
Online Access:https://doi.org/10.1111/jdi.13108
id doaj-462ca5ec2f524d3aa1bb0e47de7c329c
record_format Article
spelling doaj-462ca5ec2f524d3aa1bb0e47de7c329c2021-05-02T09:50:24ZengWileyJournal of Diabetes Investigation2040-11162040-11242020-01-01111808710.1111/jdi.13108Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patientsChisaki Ishibashi0Junji Kozawa1Yoshiya Hosakawa2Sho Yoneda3Takekazu Kimura4Yukari Fujita5Kenji Fukui6Hiromi Iwahashi7Iichiro Shimomura8Department of Metabolic MedicineGraduate School of MedicineOsaka University SuitaJapanDepartment of Metabolic MedicineGraduate School of MedicineOsaka University SuitaJapanDepartment of Metabolic MedicineGraduate School of MedicineOsaka University SuitaJapanDepartment of Metabolic MedicineGraduate School of MedicineOsaka University SuitaJapanDepartment of Metabolic MedicineGraduate School of MedicineOsaka University SuitaJapanDepartment of Metabolic MedicineGraduate School of MedicineOsaka University SuitaJapanDepartment of Metabolic MedicineGraduate School of MedicineOsaka University SuitaJapanDepartment of Metabolic MedicineGraduate School of MedicineOsaka University SuitaJapanDepartment of Metabolic MedicineGraduate School of MedicineOsaka University SuitaJapanAbstract Aims/Introduction The relationship between pancreatic fatty infiltration and diabetes is widely known, whereas the causal relationship is not clear. Furthermore, it is uncertain whether pathogenesis of pancreatic fat is similar to that of liver fat. We aimed to clarify the contribution of this type of fat to glucose metabolism in type 2 diabetes patients by cross‐sectional and longitudinal analyses. Material and Methods A total of 56 patients with type 2 diabetes who had been hospitalized twice were analyzed. We evaluated the mean computed tomography values of the pancreas (P), liver (L) and spleen (S). Lower computed tomography values indicate a greater fat content. We defined indices of pancreatic or liver fat content as the differences between P or L and S. We assessed the associations among fat content for the two organs (P‐S, L‐S) and clinical parameters at the first hospitalization, and then analyzed the associations between these fat contents and changes in glycometabolic markers (the second data values minus the first). Results In the cross‐sectional study, P‐S negatively correlated with the increment of C‐peptide in the glucagon stimulation test (r = −0.71, P < 0.0001) and body mass index (r = −0.28, P = 0.034). L‐S negatively correlated with homeostasis model assessment of insulin resistance (r = −0.73, P < 0.0001), body mass index (r = −0.62, P < 0.0001) and some other obesity‐related indicators, but not with the increment of C‐peptide in the glucagon stimulation test. In the longitudinal study, P‐S positively correlated with the change of the increment of C‐peptide in the glucagon stimulation test (r = 0.49, P = 0.021). Conclusions In type 2 diabetes patients, pancreatic fat was less associated with obesity‐related indicators than liver fat, but was more strongly associated with the longitudinal decrease in endogenous insulin‐secreting capacity.https://doi.org/10.1111/jdi.13108Insulin secretion capacityPancreatic fatType 2 diabetes
collection DOAJ
language English
format Article
sources DOAJ
author Chisaki Ishibashi
Junji Kozawa
Yoshiya Hosakawa
Sho Yoneda
Takekazu Kimura
Yukari Fujita
Kenji Fukui
Hiromi Iwahashi
Iichiro Shimomura
spellingShingle Chisaki Ishibashi
Junji Kozawa
Yoshiya Hosakawa
Sho Yoneda
Takekazu Kimura
Yukari Fujita
Kenji Fukui
Hiromi Iwahashi
Iichiro Shimomura
Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients
Journal of Diabetes Investigation
Insulin secretion capacity
Pancreatic fat
Type 2 diabetes
author_facet Chisaki Ishibashi
Junji Kozawa
Yoshiya Hosakawa
Sho Yoneda
Takekazu Kimura
Yukari Fujita
Kenji Fukui
Hiromi Iwahashi
Iichiro Shimomura
author_sort Chisaki Ishibashi
title Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients
title_short Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients
title_full Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients
title_fullStr Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients
title_full_unstemmed Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients
title_sort pancreatic fat is related to the longitudinal decrease in the increment of c‐peptide in glucagon stimulation test in type 2 diabetes patients
publisher Wiley
series Journal of Diabetes Investigation
issn 2040-1116
2040-1124
publishDate 2020-01-01
description Abstract Aims/Introduction The relationship between pancreatic fatty infiltration and diabetes is widely known, whereas the causal relationship is not clear. Furthermore, it is uncertain whether pathogenesis of pancreatic fat is similar to that of liver fat. We aimed to clarify the contribution of this type of fat to glucose metabolism in type 2 diabetes patients by cross‐sectional and longitudinal analyses. Material and Methods A total of 56 patients with type 2 diabetes who had been hospitalized twice were analyzed. We evaluated the mean computed tomography values of the pancreas (P), liver (L) and spleen (S). Lower computed tomography values indicate a greater fat content. We defined indices of pancreatic or liver fat content as the differences between P or L and S. We assessed the associations among fat content for the two organs (P‐S, L‐S) and clinical parameters at the first hospitalization, and then analyzed the associations between these fat contents and changes in glycometabolic markers (the second data values minus the first). Results In the cross‐sectional study, P‐S negatively correlated with the increment of C‐peptide in the glucagon stimulation test (r = −0.71, P < 0.0001) and body mass index (r = −0.28, P = 0.034). L‐S negatively correlated with homeostasis model assessment of insulin resistance (r = −0.73, P < 0.0001), body mass index (r = −0.62, P < 0.0001) and some other obesity‐related indicators, but not with the increment of C‐peptide in the glucagon stimulation test. In the longitudinal study, P‐S positively correlated with the change of the increment of C‐peptide in the glucagon stimulation test (r = 0.49, P = 0.021). Conclusions In type 2 diabetes patients, pancreatic fat was less associated with obesity‐related indicators than liver fat, but was more strongly associated with the longitudinal decrease in endogenous insulin‐secreting capacity.
topic Insulin secretion capacity
Pancreatic fat
Type 2 diabetes
url https://doi.org/10.1111/jdi.13108
work_keys_str_mv AT chisakiishibashi pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients
AT junjikozawa pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients
AT yoshiyahosakawa pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients
AT shoyoneda pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients
AT takekazukimura pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients
AT yukarifujita pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients
AT kenjifukui pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients
AT hiromiiwahashi pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients
AT iichiroshimomura pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients
_version_ 1721493177215483904